Page 68 - 81_04

Pirfenidone experience in mild-to-moderate Idiopathic Pulmonary Fibrosis in a General Hospital

effectiveness and toxicity in the longer term. Taking into
account high cost of pirfenidone, will be necessary
perform economic evaluations in order to identify those
patients that reach a greater clinical benefit with the lower
cost possible. This type of analysis is necessary if we
consider the availability of alternative therapy (nintedanib)
for the same clinical objective.

6. CONFLICT OF INTEREST

None.

7. REFERENCES

1. Du Bois RM, Weycker D, Albera C, Bradford WZ,
Costabel U, Kartashov A, et al. Ascertainment of
individual risk of mortality for patients with idiopathic
pulmonary fibrosis. American journal of respiratory
and critical care medicine. 2011; 184(4): 459-66.

2. Naik PK, Moore BB, Viral infection and aging as
cofactors for the development of pulmonary fibrosis,
Expert Rev Respir Med. 2010 Dec; 4(6): 759-71.

3. Raghu G, Collard HR, Egan JJ, et al. An official
ATS/ERS/JRS/ALAT statement: idiopathic
pulmonary fibrosis: evidence-based guidelines for
diagnosis and management.Am J Respir Crit Care
Med. 2011 Mar 15; 183(6): 788-824.

4. Homer RJ, Elias JA, Lee CG, Herzog E. Modern
concepts on the role of inflammation in pulmonary
fibrosis. Archives of pathology & laboratory
medicine. 2011; 135(6): 780-8.

5. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart
JS, Brown KK. Fibroblast foci are not discrete sites of
lung injury or repair: the fibroblast reticulum.
American journal of respiratory and critical care
medicine. 2006; 174(6): 654-8.

6. Xaubet A, Ancochea J, Bollo E, et al. Guidelines for
the diagnosis and treatment of idiopathic pulmonary
fibrosis. Arch Bronconeumol. 2013; 49(8):343–353

7. García CZ, Díez J de M, Walther RÁ-S. Patología
respiratoria: manual de tratamientos. Gráf. Enar; 2009.
374 p.

8. Noble PW, Albera C, Bradford WZ, Costabel U,
Glassberg MK, Kardatzke D, et al. Pirfenidone in
patients with idiopathic pulmonary fibrosis
(CAPACITY): two randomised trials. Lancet. 2011;
377(9779): 1760-9.

9. King TE, Jr., Bradford WZ, Castro-Bernardini S,
Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3
trial of pirfenidone in patients with idiopathic
pulmonary fibrosis. The New England journal of
medicine. 2014; 370(22): 2083-92.

@Real Academia Nacional de Farmacia. Spain 337